CVS Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $92.28
Market Cap (MRQ) $117.93B
P/E (TTM) 24.3
EPS (TTM) $3.79
Revenue (TTM) $415.09B
Div Yield 2.9%
ROE (TTM) 6.2%
Debt/Equity 0.0
52W Range $70–$111

CVS Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 4
Ex-date Split Type
June 7, 2005 2-for-1 Forward
June 16, 1998 2-for-1 Forward
March 15, 1989 2-for-1 Forward
May 3, 1983 2-for-1 Forward

About CVS Health Corporation Common Stock Company overview from Wikipedia

05 · wikidata

CVS Health Corporation is an American multinational healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands. The company is the world's second largest healthcare company, behind UnitedHealth Group. In 2023, the company was ranked 64th in the Forbes Global 2000. CVS started in Lowell, Massachusetts by brothers Stanley and Sidney Goldstein and their partner Ralph Hoagland. The name stood for Consumer Value Stores.

History

1960s

The first Consumer Value Store (CVS), selling health and beauty products, was founded in 1963, in Lowell, Massachusetts, by brothers Stanley and Sidney Goldstein and Ralph Hoagland. By 1964, CVS had 17 stores that sold primarily beauty products. In 1967, CVS opened its first stores with pharmacy departments in Warwick, Rhode Island, and Cumberland, Rhode Island. CVS was sold to Melville Corporation in 1969.

1970s

By 1970, CVS was operating 100 stores in New England and the Northeast. In 1972, CVS acquired 84 Clinton Drug and Discount Stores. This purchase introduced CVS to the Midwest with stores in Indiana. During 1977, CVS acquired 36 New Jersey–based Mack Drug stores.

1980s

In 1983, CVS began providing home health care for hemophilia. The company acquired Heartland Drug in 1988, a small pharmacy company in the Boston area giving it stores in the Boston metro including Watertown Square and Harvard Square.

1990s

CVS acquired 500 Peoples Drug stores in 1990, establishing the company in new mid-Atlantic markets including Washington, D.C., Pennsylvania, Maryland and Virginia. In 1994, it launched PharmaCare, a pharmacy benefit management (PBM) company. CVS became a standalone company trading on the New York Stock Exchange under the "CVS" ticker in 1996. Stanley Goldstein was the company's first chairman. CVS acquired over 2,500 Revco drug stores, establishing the company in additional Midwestern, Southeastern and Eastern states in 1997.

In 1998, the company acquired 207 stores from Arbor Drugs, giving CVS its first stores in Michigan. A year later, CVS acquired Soma.com, the first online pharmacy, and renamed it CVS.com to become the first fully integrated online and brick-and-mortar pharmacy offering to consumers.

2000s

In 2000, CVS acquired Stadtlander pharmacy from Bergen Brunswig Corporation, making CVS ProCare the largest specialty pharmacy in the U.S. at the time. In 2001, CVS launched the ExtraCare loyalty card program. Within a year, 30 million customers enrolled to earn rewards and receive discounts. CVS purchased 1,268 Eckerd drug stores and Eckerd Health Services, Eckerd's PBM/Mail-order pharmacy business, from JCPenney in 2004. The purchase expanded the company's footprint in Texas, Florida and other southern states.

2006 saw CVS acquiring 700 freestanding drug store operations of supermarket chain Albertsons, including stores trading under the Osco Drug and Sav-On Drugs banners. That same year, it acquired Minneapolis-based MinuteClinic. CVS Corporation and Caremark Rx, Inc. completed their transformative merger in 2007, creating CVS Caremark, an integrated pharmacy services provider, and the corporate headquarters remained in Woonsocket, RI. Tom Ryan, the chairman and CEO of CVS remained president and CEO of CVS Caremark Corporation, while Caremark's Edwin Crawford became the chairman of the board. CVS Caremark acquired 541 stores from Longs Drugs Stores Corp in California, Hawaii, and Nevada in 2008.

2010s

2011 saw Larry Merlo succeeding Tom Ryan as president and CEO of CVS Caremark. Merlo joined CVS/pharmacy in 1990, through the acquisition of Peoples Drug. On September 3, 2014, it was announced that CVS, as of midnight Tuesday September 2, 2014, would no longer sell tobacco products at all of its 7,700 locations nationwide, a month earlier than planned. It also announced it would change its corporate name to CVS Health to reflect "its broader health care commitment" and a desire to change the future health of Americans, although all retail stores would continue to be called "CVS/pharmacy", unless they did not contain a pharmacy, in which case they are just signed CVS. On February 5, 2014, CVS announced that the company would discontinue the sale of all tobacco and cigarette products from their stores by October 1, 2014. CVS Caremark acquired Coram in 2014, the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group Inc. That same year, the company acquired 33 Miami-based Navarro Discount Pharmacy stores, the largest Hispanic-owned drugstore chain the United States. A year later in 2015, it acquired Omnicare, provider of pharmacy services to long-term care facilities. CVS Health acquired Target's 1,600+ pharmacies and retail medical clinics inside Target stores that same year. CVS has begun operating them through a store-within-a-store format.

CVS announced they would be installing 25 vending machines in high traffic areas like, bus terminals, airports, and college campuses in 2017. The first kiosks will be located in LaGuardia Airport and Boston's South Station Bus Terminal and will carry personal items such as toothpaste, deodorant, batteries, and healthy snack foods. In December, CVS announced they agreed to buy health insurer Aetna for about $207 per share, broken down into $145 in cash and the rest in stock, in December 2017. If approved, it would allow CVS to provide a broad range of health services to Aetna's 22 million medical members. On December 5, 2017, The Wall Street Journal reported that there was still a $69 billion deal pending between CVS and Aetna, so long as it received government approval. CVS CEO Larry Merlo had been named to run the combined company. In November 2018, CEO Larry Merlo told USA Today that the drugstore chain plans to renovate its stores to focus more on health care and less on retail following its merger with the health insurance company Aetna. The new strategy is to offer medical services along with prescription drugs, among other products. On June 4, 2019, USA Today reported on the planned expansion of a CVS Health store concept called HealthHUB to 1,500 locations by the end of 2021. The concept, launched in the Houston area in early 2019, realigns CVS retail outlets with a stronger focus on health care services. HealthHUB stores dedicate at least 20% of their floor space to health care services such as yoga classes and enlarged Minute Clinic spaces to offer more health assessments. To accommodate HealthHUB, CVS locations will reduce the floor space currently devoted to slower-selling merchandise, such as greeting cards. The store conversions to the HealthHUB format was paused in March 2020, due to the COVID-19 pandemic.

2020s

In February 2020, CVS announced changes to its board of directors, whose size was reduced from 16 to 13 directors. On November 18, 2021, the company announced that it plans to close 900 stores nationwide over the next three years because of what executives described as changes in consumer shopping behavior, population, and the future of health care needs. The closures would represent approximately 10 percent of stores in the US. On November 23, 2021, federal jury found that CVS, along with Walgreens and Walmart, "had substantially contributed to" the opioid crisis.

On December 2, 2021, CVS announced a strategic partnership with Microsoft to improve personalized care and digital health. In September 2022, CVS Health announced that it reached an agreement to buy at-home health company Signify Health for roughly $8 billion. It came one month after it announced a plan to move into primary care by the end of the year. On February 8, 2023, the company announced it has entered into a definitive agreement to acquire Oak Street Health in an all-cash transaction at $39 per share, representing an enterprise value of approximately $10.6 billion. The merger was completed in May 2023.

Finances

Subsidiaries and assets

Aetna

Aetna Inc. is an American managed health care company that sells traditional and consumer directed health care insurance and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans, primarily through employer-paid (fully or partly) insurance and benefit programs, and through Medicare.

CVS Pharmacy

CVS Pharmacy is one of the largest retail pharmacy chains in the United States, with 9,600 stores located in all 50 states, the District of Columbia, and Puerto Rico, operating primarily under the CVS Pharmacy, CVS, Longs Drugs, Navarro Discount Pharmacy and Drogaria Onofre names. CVS Pharmacy fills more than one of every five prescriptions in the United States, and 85% of U.S. population lives within 10 miles of a CVS Pharmacy. The ExtraCare loyalty program boasts over 70 million cardholders, making it the largest retail loyalty program in the country.

MinuteClinic

MinuteClinic retail medical clinics operate inside CVS Pharmacy locations within the United States. It is the largest walk-in medical clinic in the United States, with over 1,100 locations in 33 states and the District of Columbia. More than 50 percent of the U.S. population now lives within 10 miles of a MinuteClinic.

CVS Caremark

CVS Caremark provides comprehensive prescription benefit management services including mail order pharmacy services, specialty pharmacy and infusion services, plan design and administration, formulary management and claims processing. The company's clients are primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans and other sponsors of health benefit plans and individuals throughout the United States. CVS Caremark manages the dispensing of prescription drugs for more than 75 million plan members through five mail order pharmacies, specialty pharmacies, long-term care pharmacies and national network of more than 68,000 retail pharmacies, consisting of approximately 41,000 chain pharmacies and 27,000 independent pharmacies.

CVS Media Exchange

CVS Media Exchange (CMX) is CVS Health's retail media network, launched in 2020.

CVS Specialty

CVS Specialty is the specialty pharmacy division that provides specialty pharmacy services for individuals with chronic or genetic diseases who require complex and expensive drug therapies. CVS Health operate 24 retail specialty pharmacy stores and 11 specialty mail order pharmacies, making them the largest specialty pharmacy in the United States.

Longs Drugs

Longs Drugs is a retail pharmacy chain with approximately 40 drug stores throughout the state of Hawaii. Prior to its acquisition by CVS in 2008, it was a chain of over 500 stores located primarily on the west coast of the United States. The stores in states other than Hawaii were rebranded to CVS.

Navarro Discount Pharmacies

Navarro Discount Pharmacies is a pharmacy chain, photo service, and pharmacy benefit manager in the United States. The company was acquired by CVS Health in September 2014, and is operated as a separate brand of CVS Health. The company mainly operates in Miami-Dade and Broward Counties and currently has 33 stores.

Accordant

Accordant provides rare disease case management and care management services for patients with rare, chronic diseases and their caregivers. Clients are primarily health plans, employers, and third party administrators (TPAs). The company is operated as a wholly owned subsidiary of CVS Health Corporation.

Coram

Coram is one of the nation's largest providers of infusion services, clinical and compliance monitoring and individual patient counseling and education. Coram cares for 140,000 patients annually through a national network of more than 85 locations as well as the largest home infusion network in the United States. The company was acquired by CVS Health in August 2015, and is operated as a wholly owned subsidiary of CVS Health Corporation.

Omnicare

Omnicare is a provider of pharmacy services to the long-term care market for patients in skilled nursing and assisted living facilities throughout North America. The company was acquired by CVS Health in August 2015, and is operated as a wholly owned subsidiary of CVS Health Corporation.

HealthHUB

HealthHUBs operate inside of select CVS Pharmacy locations and offer a variety of additional services in addition to traditional CVS locations. HealthHUB locations offer and expanded variety of Sleep Apnea, Durable Medical Equipment, Home and Health technology, and compression therapy. HealthHUBs are staffed by Care Concierges who are experts in HealthHub products and services. In addition, MinuteClinic locations that are HealthHub stores have expanded services and hire Medical Assistants, Registered Nurses, and Licensed Practical and Vocational Nurses to help support the Nurse Practitioners and Physician Assistants.

Store brands and private label brands

CVS Health offers a number of over-the-counter private label brands in their retail pharmacy stores, including grocery brands Gold Emblem™ and Gold Emblem Abound™; household products under the Total Home name; preservative-free vitamins and supplements under the Radiance PLATINUM line; and beauty and skin products through the Beauty 360, Nuance Salma Hayek, Makeup Academy, Skin+Pharmacy, Blade and Essence of Beauty lines.

Criticism and controversy

Health and Medicare fraud

In the late 1980s and early 1990s, Caremark RX was involved in a number of health fraud and Medicare fraud scandals.

The combined price to settle this dispute with the U.S. Government cost the company over $250 million.

Elensys

In 1998, The Washington Post reported that CVS Corporation appeared to be sharing prescription drug information with the Woburn, Massachusetts, based marketing company, Elensys. According to the Post, Elensys received information on specific prescription drugs that individual CVS customers had purchased and used this information to send targeted direct mailings urging customers to renew prescriptions and promoting other products in which they might be interested. CVS and Elensys argued that there were no privacy issues because Elensys was acting solely as a contractor to CVS, and because the purpose of the mailings was to educate consumers. CVS claimed that it never shared customers' medical histories with Elensys (despite The Washington Post's indirect evidence that they had). George D. Lundberg, editor of the Journal of the American Medical Association, called the practice "a gross invasion" of privacy. Following a firestorm of criticism and complaints by consumers, CVS discontinued the relationship with Elensys, and moved the practice in-house.

Trio Drugs Lawsuit

On August 22, 2001, CVS Corp was sued for purchasing Trio Drugs' confidential records.

Boston prescriptions

During 2005, a series of prescription mistakes came to light in some of CVS Corporation's Boston-area stores. An investigation confirmed 62 errors or quality problems going back to 2002. In February 2006, the state Board of Pharmacy announced that the non-profit Institute for Safe Medication Practices (ISMP) would monitor all Massachusetts stores for the next two years.

Restatements

On November 15, 1999, CVS announced a restatement of its financial results for 1997, and 1998, following a Securities and Exchange Commission review of acquisition-related charges.

On February 25, 2005, CVS said it was reducing its previously announced fourth-quarter earnings by $40.5 million, to reflect the way it accounted for leased properties in its results.

Pharmaceutical kickbacks

In 2005, Caremark Rx paid $137.5 million to settle federal lawsuits filed by whistleblowers that accused a company it acquired in 2003, of improper dealings with pharmaceutical manufacturers.

The lawsuits said that the acquired company, AdvancePCS, accepted kickbacks from drug makers to promote their products over those of rivals under contracts with government programs including the Federal Employees Health Benefit Program, the Mail Handlers Health Benefit Program and Medicare health maintenance plans.

There was no admission of wrongdoing by Caremark or AdvancePCS.

CVS Caremark Corp. has changed their practices. The formulary revision process considers manufacturer rebates, payments from drug manufacturers for low placement on PBM (Pharmacy Benefit Manager) formularies, along with average wholesale price (AWP), drug availability, and bulk discounts when choosing at which co-pay a brand name drug should be placed.

Deceptive business practices

In February 2008, CVS settled a large civil lawsuit for deceptive business practices. The Kaiser Family Foundation reported:

CVS has agreed to a $38.5 million settlement in a multi-state civil deceptive-practices lawsuit against pharmacy benefit manager Caremark filed by 28 attorneys general, the Chicago Tribune reports. The attorneys general, led by Lisa Madigan (D) of Illinois and Douglas Ganslar (D) of Maryland, allege that Caremark "engaged in deceptive business practices" by informing physicians that patients or health plans could save money if patients were switched to certain brand-name prescription drugs (Miller, Chicago Tribune, 2/14).

However, the switch often saved patients and health plans only small amounts or increased their costs, while increasing Caremark's profits, Connecticut Attorney General Richard Blumenthal (D) said (Levick, Hartford Courant, 2/15). Pennsylvania Attorney General Tom Corbett (R) said the Pharmacy Benefit Manager (PBM), kept discounts and rebates that should have been passed on to employers and patients (Levy, AP/San Francisco Chronicle, 2/14). In addition, Caremark did not "adequately inform doctors" of the full financial effect of the switch and did not disclose that the switch would increase Caremark's profits, the lawsuit alleges (Chicago Tribune, 2/14).

...The settlement prohibits CVS from requesting prescription drug switches in certain cases, such as when the cost to the patient would be higher with the new prescription drug; when the original prescription drug's patent will expire within six months; and when patients were switched from a similar prescription drug within the previous two years (Hartford Courant, 2/15). Patients also have the ability to decline a switch from the prescribed treatment to the prescription offered by the pharmacy under the settlement, Madigan said (Bloomberg News/The Philadelphia Inquirer, 2/15).

Rhode Island Senate corruption case

In 2008, two former CVS executives, John R. "Jack" Kramer and Carlos Ortiz, were charged with 20 counts of mail fraud, bribery and conspiracy in relation to Operation Dollar Bill, a probe of corruption in the Rhode Island General Assembly. Kramer and Ortiz hired former state senator John Celona, who currently is serving 2+1⁄2 years on corruption charges involving CVS and other companies, as a media consultant for $12,000 a year. Celona was known for walking out on a pharmacy choice vote in the state senate while on the CVS payroll. Despite originally claiming CVS never bought any favors in his own trial, he testified against Kramer and Ortiz as the prosecution's star witness. On May 31, 2008, Kramer and Ortiz were acquitted on all counts. One juror went on the record as saying "My perception living in Rhode Island all my life is, 'Yeah, this probably did go on', but I didn't see any proof beyond a reasonable doubt that CVS did this."

Privacy violations

On February 18, 2009, CVS Caremark agreed to settle Federal Trade Commission charges that it failed to take reasonable and appropriate security measures to protect the sensitive financial and medical information of its customers and employees, in violation of federal law. In a separate but related agreement, the company's pharmacy chain also has agreed to pay $2.25 million to resolve Department of Health and Human Services allegations that it violated the Health Insurance Portability and Accountability Act (HIPAA).

In September 2026, CVS entered into a $20.5 million class action settlement after a lawsuit alleged that CVS disclosed customers' personal data to advertising company Criteo.

Business practices under investigation

On May 4, 2010, CVS Caremark Corp. announced that its business practices were being investigated by a group of 24 states, along with the District of Columbia and Los Angeles County. At issue is the post-merger relationship between CVS and Caremark. In addition, the company had earlier acknowledged in a filing with the Securities and Exchange Commission (SEC) that it had received a subpoena from the Office of Inspector General of the United States Department of Health and Human Services, requiring the company to provide information regarding the incentives the company provides to customers who transfer their prescriptions to CVS, including gift cards, goods and other incentives.

DEA investigation into oxycodone diversion

According to the U.S. Justice Department, in 2011, CVS pharmacies in Sanford, Florida, ordered enough painkillers to supply a population eight times its size. Sanford has a population of 53,000 but the supply would support 400,000. According to the Drug Enforcement Administration, in 2010, a single CVS pharmacy in Sanford ordered 1.8 million Oxycodone pills, an average of 137,994 pills a month. Other pharmacy customers in Florida averaged 5,364 oxycodone pills a month. DEA investigators serving a warrant to a CVS pharmacy in Sanford on October 18, 2011, noted that "approximately every third car that came through the drive-thru lane had prescriptions for oxycodone or hydrocodone". According to the DEA, a pharmacist at that location stated to investigators that "her customers often requested certain brands of oxycodone using street slang", an indicator that the drugs were being diverted and not used for legitimate pain management. In response, CVS in a statement issued February 17 in response to opioid trafficking questions from USA Today said the company is committed to working with the DEA and had taken "significant actions to ensure appropriate dispensing of painkillers in Florida".

FTC charges of deceptive pricing

On January 12, 2012, CVS Caremark paid $5 million to settle Federal Trade Commission charges that it misrepresented the prices of certain Medicare Part D prescription drugs – including drugs used to treat breast cancer symptoms and epilepsy – at CVS and Walgreens pharmacies.

Co-responsibility for opioid crisis

In September 2016, Massachusetts Attorney General Maura Healey announced a $795,000 settlement where CVS agrees to check a state database before filling the prescription for addictive opioids and other controlled substances. The settlement resolves previous allegations that the drugstore chain failed to provide pharmacists with access to the state of Massachusetts Prescription Monitoring Program (PMP). In July 2020, the attorney general of the Commonwealth of Kentucky filed a lawsuit against CVS alleging that their business practices aided in the advancing of the opioid epidemic.

In November 2021, a federal jury in Cleveland found that pharmacies operated by CVS Health, Walgreens, and Walmart were liable for contributing to the opioid epidemic in two Ohio counties. The trial lasted six weeks with the jury returning a verdict finding the Ohio pharmacies liable. It was the first trial where pharmacy companies defended themselves amidst the opioid epidemic.

In August 2022, the company was one of three chains ordered to pay damages of $650 million by a Cleveland judge in a lawsuit over opioid sales brought on by Lake County and Trumbull County in Ohio. The other two chains were Walgreens and Walmart, with two others, Rite Aid and Giant Eagle, settling before going to trial. Lawyers representing the counties claimed damages of $3.3 billion.

CFI lawsuit for consumer fraud

In July 2018, the Center for Inquiry filed a lawsuit against CVS for consumer fraud over its sale of homeopathic medicines. The filing in part contends that apart from being a waste of money, choosing homeopathic treatments to the exclusion of evidence-based medicines can result in worsened or prolonged symptoms, and in some cases, even death.

Abortion pill controversy

In January 2023, CVS announced their intentions to start dispensing mifepristone, one of the two drugs used in a medication abortion, following a change in regulations from the Food and Drug Administration. After receiving their certification to do so, CVS started offering abortion pills in jurisdictions where they are legal. The offering of abortion pills at pharmacies such as CVS has caused major political turmoil, and has resulted in numerous protests in-front of the pharmacies.

Pharmacists mistakenly cause an abortion

In October 2023, CVS mistakenly gave misoprostol, an abortion pill, to Tamika Thomas, a woman undergoing IVF who was supposed to be receiving a medication to help kick-start her pregnancy. In an interview with 8 News Now, Thomas stated she knew something was wrong when she experienced major cramping. "My cramping went beyond that. It was extreme. It was painful." As a result of the medication, Tamika lost both of her embryos. She stated, "They just killed my baby … Both my babies, because I transferred two embryos."

At the hearing, one of the pharmacists stated, "It's a human error. It was just a human error, and I'm so sorry." The two pharmacists were fined and placed on probation for one year. CVS Pharmacy was given a maximum fine of $10,000. The pharmacists will be able to return to work after one year if all conditions are met.

Animal welfare

In 2016, CVS committed to source 100% cage-free eggs by 2025, responding to pressure from animal welfare groups. In 2023, CVS announced that they reached this goal ahead of schedule, on December 31, 2022.

Community involvement and philanthropy

Since 1978, CVS Samaritan Vans have provided free roadside assistance to motorists and the community in numerous cities.

Played at the Rhode Island Country Club, the CVS Caremark Charity Classic was established to raise money for the support of non-profit agencies throughout New England. Since 1999, it has raised over $8 million for charity.

In 2024, CVS Health committed to invest nearly $35 million in equity to create two affordable housing developments in Hawai'i. A $17.5 million investment went toward the construction of 200 new affordable housing units at Kaiāulu o Kūku'ia (Lahaina, Maui), while another $17.3 million, along with The Kobayashi Group, The Ahe Group and CREA, LLC, was invested in the construction of 169 new affordable housing units at Parkway Village (Kapolei, Oahu).

Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗

Wikidata ↗

sectorHealth Care industryHealth Care employees219,000 countryUS

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$402.07B
2017-12-31 → 2025-12-31
EPS$1.39
2017-12-31 → 2025-12-31
Free Cash Flow$7.81B
2017-12-31 → 2025-12-31
Net margin1.2%
2017-12-31 → 2025-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend CVS 5Y avg Peer Median Verdict
P/E (TTM) 24.35Y avg ≈25.5 ≈25.5 23.3 Overvalued
P/S (TTM) 0.35Y avg ≈0.3 ≈0.3 1.3 Undervalued
P/B (MRQ) 1.55Y avg ≈1.4 ≈1.4 3.0 Undervalued
EV / EBITDA 11.55Y avg ≈6.1 ≈6.1 11.4 Undervalued
Price / FCF (TTM) 10.05Y avg ≈9.9 ≈9.9 · ·
Price / Cash Flow (TTM) 8.05Y avg ≈7.6 ≈7.6 9.8 Fair value
EV / Revenue 0.35Y avg ≈0.2 ≈0.2 · ·
EV / FCF 13.75Y avg ≈9.3 ≈9.3 · ·
Price / Tangible Book (MRQ) 2.1 · · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Dividends Yield, payout ratio, dividend history, 5Y CAGR

13
Dividend Yield2.9%
Payout Ratio192.1%
Annualized Payout≈$2.66Paid quarterly
5Y Div CAGR≈5.9%Per share, split-adjusted
Ex-dateAmountCurrencyYield
Oct 22, 2026$0.67USD≈2.8%
Jul 23, 2026$0.67USD≈2.5%
Apr 23, 2026$0.67USD≈3.4%
Jan 22, 2026$0.67USD≈3.2%
Oct 23, 2025$0.67USD≈3.3%
Jul 22, 2025$0.67USD≈4.4%
Apr 22, 2025$0.67USD≈4.1%
Jan 23, 2025$0.67USD≈4.9%
Oct 21, 2024$0.67USD≈4.6%
Jul 22, 2024$0.67USD≈4.5%
Apr 19, 2024$0.67USD≈3.6%
Jan 19, 2024$0.67USD≈3.4%
Oct 19, 2023$0.61USD≈3.4%
Jul 20, 2023$0.61USD≈3.2%
Apr 20, 2023$0.61USD≈3.2%
Jan 19, 2023$0.61USD≈2.6%
Oct 20, 2022$0.55USD≈2.4%
Jul 21, 2022$0.55USD≈2.3%
Apr 21, 2022$0.55USD≈2.0%
Jan 20, 2022$0.55USD≈2.0%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise 22.0%
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Jul 29, 2026 $2.58 $1.87 38.0%
March 31, 2026 $2.57 $2.22 15.8%
Dec. 31, 2025 $1.09 $1.00 8.8%
Sept. 30, 2025 $1.60 $1.38 15.7%
June 30, 2025 $1.81 $1.47 23.0%
March 31, 2025 $2.25 $1.72 30.8%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 16
Metric Trend 20252024202320222021202020192018201720162015
Revenue $402.07B$372.81B$357.78B$322.47B$292.11B$268.71B$256.78B·$184.79B$177.55B$153.29B
Cost of Revenue $221.17B$206.29B$217.10B$196.89B$175.80B$163.98B$158.72B·$153.45B$146.53B$126.76B
Gross Profit ········$28.55B$28.86B$26.53B
Operating Expenses $397.41B$364.29B$344.03B$314.51B$278.80B$254.79B$244.79B·$18.81B$18.45B$17.05B
Operating Income $4.66B$8.52B$13.74B$7.95B$13.31B$13.91B$11.99B·$9.54B$10.39B$9.47B
Interest Expense ··$2.66B$2.29B$2.50B$2.91B$3.04B·$1.06B$1.08B$859M
Interest Income ········$21M$20M$21M
Other Non-op $112M$99M$88M$169M$182M$206M$124M·$-208M$-28M·
Pretax Income $2.14B$6.15B$11.17B$5.84B$10.54B$9.77B$9.00B·$8.27B$8.64B$8.62B
Income Tax $408M$1.56B$2.81B$1.51B$2.55B$2.57B$2.37B·$1.64B$3.32B$3.39B
Net Income $1.77B$4.61B$8.34B$4.31B$8.00B$7.18B$6.63B·$6.62B$5.32B$5.24B
EPS (Basic) $1.40$3.67$6.49$3.29$6.07$5.48$5.10·$6.47$4.93$4.66
EPS (Diluted) $1.39$3.66$6.47$3.26$6.02$5.46$5.08·$6.44$4.90$4.63
Shares (Basic) 1,267,000,0001,259,000,0001,285,000,0001,312,000,0001,319,000,0001,309,000,0001,301,000,000·1,020,000,0001,073,000,0001,118,000,000
Shares (Diluted) 1,271,000,0001,262,000,0001,290,000,0001,323,000,0001,329,000,0001,314,000,0001,305,000,000·1,024,000,0001,079,000,0001,126,000,000
EBITDA $9.27B$13.11B$18.11B$11.99B$17.70B$18.35B$16.36B·$12.00B$10.34B$9.45B
Balance Sheet 31
Metric Trend 20252024202320222021202020192018201720162015
Cash & Equivalents $8.45B$8.59B$8.20B$12.95B$9.41B$7.85B$5.68B·$1.70B$3.37B$2.46B
Short-term Investments $2.15B$2.41B$3.26B$2.78B$3.12B$3.00B$2.37B·$111M$87M$88M
Receivables $39.78B$36.47B$35.23B$27.28B$24.43B$21.74B$19.62B·$13.18B$12.16B$11.89B
Inventory $19.25B$18.11B$18.02B$19.09B$17.76B$18.50B$17.52B·$15.30B$14.76B$14.00B
Other Current Assets $5.09B$3.08B$3.15B$2.64B$5.29B$5.28B$5.11B$4.53B$945M$660M$722M
Current Assets $74.71B$68.64B$67.86B$65.63B$60.01B$56.37B$50.30B$45.20B$31.23B$31.04B$29.16B
PP&E (Net) ···$12.87B$12.90B$12.61B$12.04B$11.36B$10.29B$10.18B$9.86B
PP&E (Gross) ···$34.60B$33.55B$31.31B$28.93B·$24.29B$22.80B$21.04B
Accum. Depreciation ···$21.48B$20.65B$18.70B$16.89B·$14.00B$12.63B$11.18B
Goodwill $85.48B$91.27B$91.27B$78.15B$79.12B$79.55B$79.75B·$38.45B$38.25B$38.11B
Intangibles $25.51B$27.32B$29.23B$24.80B$29.03B$31.14B$33.12B$36.31B$13.63B$13.51B$13.88B
Other Non-current Assets $7.11B$4.79B$4.66B$4.62B$4.71B$4.62B$4.60B$4.53B$1.42B$1.49B$1.44B
Total Assets $253.54B$253.22B$249.73B$228.28B$233.00B$230.72B$222.45B$216.67B$95.13B$94.46B$92.44B
Accounts Payable ········$8.86B$7.95B$7.49B
Accrued Liabilities $22.39B$20.81B$23.52B$18.75B$17.67B$14.24B$12.13B$10.66B$6.58B$6.94B$6.83B
Short-term Debt $0$2.12B$200M$0·$0$0·$1.28B$1.87B$0
Current Liabilities $88.69B$84.61B$79.19B$69.42B$67.81B$62.02B$53.30B$45.76B$30.65B$26.25B$23.17B
Capital Leases $13.64B$14.90B$16.03B$16.80B$18.18B$18.76B$18.93B$18.83B$306M··
Deferred Tax $3.83B$3.81B$4.31B$4.02B$6.27B$6.79B$7.29B$7.74B$3.00B$4.21B$4.22B
Other Non-current Liabilities $6.77B$5.43B$6.21B$6.73B$1.90B$2.35B$2.16B$2.26B$1.28B$1.55B$1.54B
Total Liabilities $178.16B$177.49B$173.09B$156.51B$157.62B$161.01B$158.28B$157.95B$57.44B··
Long-term Debt ······$68.48B$72.61B$27.00B$25.70B$27.50B
Total Debt $0$2.12B$200M···$3.78B·$27.00B$27.53B$27.46B
Common Stock ·$18M$18M$18M$17M$17M$17M·$17M$17M$17M
Paid-in Capital ········$32.08B$31.62B$30.95B
Retained Earnings $61.20B$62.84B$61.60B$56.40B$54.91B$49.64B$45.11B$41.09B$43.56B$38.98B$35.51B
Treasury Stock $36.79B$36.82B$33.84B$31.86B$28.17B$28.18B$28.23B·$37.80B$33.45B$28.89B
AOCI $406M$-120M$-297M$-1.26B$965M$1.41B$1.02B·$-165M$-305M$-358M
Stockholders' Equity $75.21B$75.56B$76.46B$71.47B$75.08B$69.39B$63.86B$58.40B$37.69B$36.83B$37.20B
Liabilities + Equity $253.54B$253.22B$249.73B$228.28B$233.00B$230.72B$222.45B·$95.13B$94.46B$92.44B
Shares Outstanding 1,271,000,0001,260,000,0001,288,000,0001,300,000,0001,322,000,0001,310,000,0001,302,000,000·1,712,000,0001,061,000,0001,101,000,000
Cash Flow 19
Metric Trend 20252024202320222021202020192018201720162015
D&A $4.61B$4.60B$4.37B$4.22B$4.49B$4.44B$4.37B·$2.48B$2.48B$2.09B
Stock-based Comp $535M$540M$588M$447M$484M$400M$453M·$234M$222M$230M
Deferred Tax $102M$-572M$-676M$-2.03B$-402M$-564M$-649M·$-1.42B$3M$-234M
Amort. of Intangibles $2.00B$2.00B$1.90B$1.80B$2.20B$2.30B$2.40B·$817M$795M$611M
Restructuring ········$215M··
Other Non-cash $3.63B$-72M$804M$9.41B$5.79B$4.41B$2.04B·$93M··
Operating Cash Flow $10.64B$9.11B$13.43B$16.18B$18.27B$15.87B$12.85B·$8.01B$10.14B$8.54B
CapEx $2.83B$2.78B$3.03B$2.73B$2.52B$2.44B$2.46B·$1.92B$2.22B$2.37B
Investing Cash Flow $-5.87B$-7.61B$-20.89B$-5.05B$-5.26B$-5.53B$-3.34B·$-2.88B$-2.47B$-13.42B
Debt Issued $3.97B$7.91B$10.90B$0$987M$9.96B$3.74B·$0$3.46B$14.80B
Net Debt Issued $340M$3.14B$7.73B$-4.21B$-9.27B$-5.67B$-4.60B··$-2.49B$11.90B
Stock Repurchased $0$3.02B$2.01B$3.50B$0$0$0·$4.36B$4.46B$5.00B
Net Stock Activity $0$-3.02B$-2.01B$-3.50B··$0·$-4.36B$-4.46B$-5.00B
Dividends Paid $3.40B$3.37B$3.13B$2.91B$2.62B$2.62B$2.60B·$2.05B$1.84B$1.58B
Financing Cash Flow $-4.94B$-1.14B$2.68B$-10.52B$-11.36B$-7.70B$-7.65B·$-6.75B$-6.76B$4.88B
Net Change in Cash $-172M$359M$-4.78B$614M$1.65B$2.63B$1.85B·$-1.62B$912M$-22M
Taxes Paid $2.17B$1.70B$3.52B$4.12B$3.19B$2.93B$2.72B·$2.91B$3.06B$3.27B
Free Cash Flow $7.81B$6.33B$10.39B$13.45B$15.74B$13.43B$10.39B·$6.09B$7.84B$6.04B
Levered FCF ··$8.40B$11.76B$13.85B$11.29B$8.15B·$5.24B$7.18B$5.52B
Profitability 8
Metric Trend 20252024202320222021202020192018201720162015
Gross Margin ········15.4%16.3%17.3%
Operating Margin 1.2%2.3%3.8%2.4%4.5%5.2%4.7%·5.1%5.8%6.2%
Net Margin 0.44%1.2%2.3%1.3%2.7%2.7%2.6%·3.6%3.0%3.4%
Pretax Margin 0.53%1.7%3.1%1.8%3.6%3.6%3.5%·4.5%4.9%5.6%
EBITDA Margin 2.3%3.5%5.1%3.7%6.1%6.8%6.4%·6.5%5.8%6.2%
ROA 0.70%1.8%3.5%1.8%3.4%3.2%3.0%·7.0%5.7%6.2%
ROE 2.4%6.1%11.3%5.7%10.9%10.8%10.8%·17.8%14.4%13.9%
ROIC 5.0%8.2%13.4%8.1%13.3%14.8%13.1%·11.8%9.9%8.9%
Liquidity & Solvency 5
Metric Trend 20252024202320222021202020192018201720162015
Current Ratio 0.80.80.90.90.90.90.9·1.01.21.3
Quick Ratio 0.60.60.60.60.50.50.5·0.50.60.6
Debt / Equity 0.00.00.0···0.1·0.70.70.7
LT Debt / Equity ········0.60.70.7
Interest Coverage ··5.23.45.34.83.9·9.09.611.0
Efficiency 3
Metric Trend 20252024202320222021202020192018201720162015
Asset Turnover 1.61.51.51.41.31.21.2·1.91.91.8
Inventory Turnover 11.811.411.710.79.79.19.3·10.410.39.8
Receivables Turnover 10.510.411.412.512.713.013.8·14.614.814.2
Per Share 7
Metric Trend 20252024202320222021202020192018201720162015
Book Value / Share $59.18$59.97$59.36$54.63$56.79$52.97$49.05·$37.17$34.71$33.78
Revenue / Share $316.34$295.41$277.35$243.74$219.80$204.49$196.76·$180.43$164.53$136.14
Cash Flow / Share $8.37$7.22$10.41$12.23$13.74$12.07$9.85·$7.82$9.33$7.47
Cash / Share $6.65$6.81$6.36$9.96$7.12$6.00$4.36·$1.67$3.18$2.23
Dividend / Share $2.66$2.66$2.42$2.20$2.00$2.00$2.00·$2.00$1.70$1.40
Dividend Paid / Share ········$2.00··
EPS (TTM) $1.39$3.66$6.47$3.26$6.02$5.46$5.08·$6.44$4.90$4.63
Growth Rates 10
Metric Trend 20252024202320222021202020192018201720162015
Revenue YoY 7.8%4.2%10.9%10.4%8.7%······
Revenue CAGR 3Y 7.6%8.5%10.0%········
Revenue CAGR 5Y 8.4%··········
EPS YoY -62.0%-43.4%98.5%-45.9%10.3%······
EPS CAGR 3Y -24.7%-15.3%5.8%········
EPS CAGR 5Y -23.9%··········
Net Income YoY -61.7%-44.7%93.5%-46.1%11.5%······
Net Income CAGR 3Y -25.7%-16.8%5.1%········
Net Income CAGR 5Y -24.4%··········
Dividends Paid CAGR 5Y 5.3%··········
Valuation (TTM) 16
Metric Trend 20252024202320222021202020192018201720162015
Revenue TTM $402.07B$372.81B$357.78B$322.47B$292.11B$268.71B$256.78B·$184.79B$177.55B$153.29B
Net Income TTM $1.77B$4.61B$8.34B$4.31B$8.00B$7.18B$6.63B·$6.62B$5.32B$5.24B
Market Cap $100.87B$56.56B$101.70B$121.15B$136.38B$89.47B$96.73B·$73.52B$83.72B$107.64B
Enterprise Value $90.27B$47.69B$90.45B···$92.45B·$98.71B$107.80B$132.56B
P/E 57.112.312.228.617.112.514.6·11.316.121.1
P/S 0.30.20.30.40.50.30.4·0.40.50.7
P/B 1.30.71.31.71.81.31.5·2.02.32.9
P / Cash Flow 9.56.27.67.57.55.67.5·9.28.312.8
P / FCF 12.98.99.89.08.76.79.3·12.110.717.8
EV / EBITDA 9.73.65.0···5.7·8.210.414.0
EV / FCF 11.67.58.7···8.9·16.213.721.9
EV / Revenue 0.20.10.3···0.4·0.50.60.9
Dividend Yield 3.4%6.0%3.1%2.4%1.9%2.9%2.7%·2.8%2.2%1.5%
Earnings Yield 1.8%8.2%8.2%3.5%5.8%8.0%6.8%·8.9%6.2%4.7%
Payout Ratio 192.1%73.1%37.5%70.1%33.2%36.5%39.2%·30.9%34.6%30.1%
Annual Payout $3.40B$3.37B$3.13B$2.91B$2.62B$2.62B$2.60B·$2.05B$1.84B$1.58B

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $402.07B $372.81B $357.78B $322.47B $292.11B
Operating Margin % 1.2% 2.3% 3.8% 2.4% 4.5%
Net Income $1.77B $4.61B $8.34B $4.31B $8.00B
Diluted EPS $1.39 $3.66 $6.47 $3.26 $6.02

Institutional owners (13F) 2,241 filers · $125.8B total · As of Sept. 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 2,241
Value held $125.8B
New positions 317
Exited positions 94
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
317 (+121 vs prior Q) 94 (-95 vs prior Q) 805 (+78 vs prior Q) 763 (-12 vs prior Q) +50.6M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
BlackRock, Inc. $12,747,461,705 123,223,409 10.14% Shares
VANGUARD GROUP INC $9,579,508,282 120,709,530 7.62% Shares
VANGUARD CAPITAL MANAGEMENT LLC $8,618,974,924 83,315,369 6.85% Shares
Capital World Investors $7,753,834,783 74,951,955 6.17% Shares
STATE STREET CORP $6,236,318,558 60,283,408 4.96% Shares
Dodge & Cox $5,173,820,539 50,012,765 4.11% Shares
WELLINGTON MANAGEMENT GROUP LLP $3,496,725,140 33,801,113 2.78% Shares
GEODE CAPITAL MANAGEMENT, LLC $3,079,404,427 29,899,653 2.45% Shares
FMR LLC $2,991,837,927 28,920,617 2.38% Shares
VANGUARD PORTFOLIO MANAGEMENT LLC $2,755,624,444 26,637,259 2.19% Shares
Capital Research Global Investors $2,516,851,376 24,329,151 2.00% Shares
BANK OF AMERICA CORP /DE/ $2,398,868,007 23,188,670 1.91% Shares
JPMORGAN CHASE & CO $2,290,461,677 22,112,970 1.82% Shares
Invesco Ltd. $2,130,597,379 20,595,431 1.69% Shares
MORGAN STANLEY $1,924,793,937 18,606,028 1.53% Shares
NORGES BANK $1,866,126,481 18,038,922 1.48% Shares
Capital International Investors $1,591,868,430 15,387,600 1.27% Shares
GOLDMAN SACHS GROUP INC $1,387,451,459 13,411,807 1.10% Shares
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $1,371,677,011 13,259,314 1.09% Shares
Davis Selected Advisers $1,227,594,458 11,865,916 0.98% Shares
PZENA INVESTMENT MANAGEMENT LLC $1,217,558,500 11,769,536 0.97% Shares
NORTHERN TRUST CORP $1,186,760,815 11,471,830 0.94% Shares
FRANKLIN RESOURCES INC $1,032,982,350 9,985,330 0.82% Shares
Legal & General Group Plc $948,946,746 9,172,999 0.75% Shares
Bank of New York Mellon Corp $932,453,862 9,013,571 0.74% Shares
Clearbridge Investments, LLC $883,116,767 8,536,952 0.70% Shares
ROYAL BANK OF CANADA $880,475,000 8,511,113 0.70% Shares
GQG Partners LLC $822,989,370 7,955,411 0.65% Shares
AMERIPRISE FINANCIAL INC $821,911,618 7,943,034 0.65% Shares
Amundi $778,468,900 7,525,080 0.62% Shares
DIMENSIONAL FUND ADVISORS LP $763,688,490 7,381,983 0.61% Shares
VANGUARD FIDUCIARY TRUST CO $741,242,940 7,165,229 0.59% Shares
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $595,969,397 8,298,098 0.47% Shares
Nuveen, LLC $544,750,652 5,265,836 0.43% Shares
UBS Group AG $544,267,107 5,261,161 0.43% Shares
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $524,415,257 5,069,263 0.42% Shares
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main $511,339,969 4,942,871 0.41% Shares
GLENVIEW CAPITAL MANAGEMENT, LLC $499,125,457 4,824,799 0.40% Shares
CITADEL ADVISORS LLC $497,856,229 4,812,530 0.40% Shares
DEUTSCHE BANK AG\ $466,633,571 4,510,716 0.37% Shares
RAYMOND JAMES FINANCIAL INC $449,870,951 4,348,680 0.36% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $409,796,485 3,961,300 0.33% Call option
Allianz Asset Management GmbH $391,245,314 3,781,975 0.31% Shares
WELLS FARGO & COMPANY/MN $380,921,357 3,682,178 0.30% Shares
VIKING GLOBAL INVESTORS LP $378,974,695 3,663,361 0.30% Shares
Swiss National Bank $371,195,152 3,588,160 0.30% Shares
National Pension Service $352,166,145 3,404,216 0.28% Shares
Assenagon Asset Management S.A. $326,699,552 3,812,575 0.26% Shares
Mitsubishi UFJ Asset Management Co., Ltd. $322,653,390 3,118,927 0.26% Shares
Russell Investments Group, Ltd. $312,682,898 3,022,292 0.25% Shares

Show all 2,241 institutional owners →

Activists & 5%+ owners 1 position

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
CVS Caremark Corporation Jan. 7, 2011 · Initial filing M&A / sale SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 86 insiders · 48 officers · 41 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
David J. Joyner President, CEO and Chair April 1, 2026 F 70,349 0 0 $0
Karen S Lynch President and CEO April 1, 2024 A 74,687 0 0 $0
Brian Newman EVP, Chief Financial Officer May 31, 2026 F 3,008 0 0 $0
Thomas F. Cowhey EVP and CFO April 1, 2025 A 41,109 0 0 $0
Shawn M Guertin EVP & Chief Financial Officer April 1, 2023 A 34,706 0 0 $0
Eva C Boratto EVP & CFO May 4, 2021 S 115,331 0 0 $0
David M Denton EVP and CFO Nov. 29, 2018 S 403 0 0 $0
David B Rickard Chief Financial Officer Dec. 14, 2009 M 207,179 0 0 $0
Howard A Mclure President, Caremark Pharm Serv Nov. 2, 2009 M 0 0 0 $0
Jonathan C Roberts EVP & Chief Operating Officer April 1, 2022 A 426,025 0 0 $0
James David Clark SVP, Cont & Chief Acct Officer June 26, 2026 F 27,606 0 0 $0
Amy Compton-Phillips EVP, Chief Medical Officer May 31, 2026 F 9,557 0 0 $0
Tilak Mandadi EVP, Chief Exp & Tech Officer May 8, 2026 S 10,133 0 1 $-6,230,379
Prem S Shah EVP and Group President March 31, 2026 A 64,356 0 0 $0
Heidi B Capozzi EVP and Chief People Officer March 31, 2026 A 13,023 0 0 $0
Samrat S. Khichi EVP, CPO and General Counsel March 31, 2026 A 33,421 0 0 $0
Steven H Nelson EVP and President, Aetna March 31, 2026 A 2,900 1 0 $1,289
Sreekanth K Chaguturu EVP and Chief Medical Officer April 1, 2024 A 23,666 0 0 $0
Laurie P. Havanec EVP and Chief People Officer April 1, 2024 A 9,426 0 0 $0
Brian A Kane EVP/President, Aetna April 1, 2024 A 12,569 0 0 $0
Finke Daniel P EVP/Pres, Health Care Benefits April 1, 2023 A 35,068 0 0 $0
Michelle A Peluso EVP and Co-President of Retail April 1, 2023 A 124,383 0 0 $0
Thomas M Moriarty EVP & General Counsel Dec. 31, 2022 F 315,273 0 0 $0
Alan Lotvin EVP&President-PharmacyServices Aug. 4, 2022 M 109,183 0 0 $0
Troyen A Brennan EVP and Chief Medical Officer April 3, 2022 F 232,676 0 0 $0
Neela Montgomery EVP and Pres., Pharmacy/Retail April 1, 2021 A 29,502 0 0 $0
Lisa Bisaccia Former EVP & Chief HR Officer April 1, 2021 F 66,417 0 0 $0
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL Feb. 28, 2021 F 25,657 0 0 $0
Jonathan E. Mayhew EVP - Transformation Dec. 2, 2020 F 6,855 0 0 $0
Derica W Rice EVP & President, CVS Caremark Feb. 28, 2020 F 26,827 0 0 $0
Kevin Hourican EVP & President, CVS Pharmacy April 1, 2019 A 15,237 0 0 $0
Helena Foulkes EVP & President-CVS Pharmacy Feb. 16, 2018 M 45,107 0 0 $0
Robert O. Kraft EVP and President - Omnicare April 3, 2017 A 92,360 0 0 $0
Andrew Sussman EVP, Clinical Services April 3, 2017 A 16,433 0 0 $0
Stephen J Gold EVP & CIO April 3, 2017 A 46,818 0 0 $0
Per Gh Lofberg EVP Jan. 2, 2015 M 23,419 0 0 $0
Mark Cosby EVP & President-CVS/pharmacy Sept. 30, 2013 M 45,955 0 0 $0
Laird Daniels SVP, Cont & Chief Acct Officer April 1, 2013 A 17,845 0 0 $0
Douglas A Sgarro EVP and CLO May 11, 2012 M 214 0 0 $0
Stuart M Mcguigan SVP and CIO March 16, 2012 M 10,967 0 0 $0
Thomas M Ryan Non-Executive Chairman April 3, 2011 F 1,156,702 0 0 $0
Sara Finley SVP, Gen Counsel Feb. 18, 2011 F 29,053 0 0 $0
Michael V Ferdinandi Senior Vice President Aug. 19, 2009 S 16,021 0 0 $0
Paula A Price Controller Feb. 12, 2008 A 16,498 0 0 $0
Edwin M Crawford Chairman Oct. 29, 2007 A 135,572 0 0 $0
William R Spalding EVP Caremark Pharmacy Services June 18, 2007 M 182 0 0 $0
Gregory S Weishar Vice President April 3, 2006 A 30,161 0 0 $0
Larry D Solberg Senior Vice President Feb. 16, 2006 A 5,978 0 0 $0
ROBBINS LARRY Director May 21, 2026 S 4,824,799 0 8 $-352,750,556
Fernando Aguirre Director May 21, 2026 D 10,513 0 0 $0
Jeffrey R. Balser Director May 14, 2026 A 15,717 0 0 $0
Douglas H. Shulman Director May 14, 2026 A 5,929 0 0 $0
Leslie V Norwalk Director May 14, 2026 A 7,376 0 0 $0
Michael F Mahoney Director May 14, 2026 A 6,345 0 0 $0
Anne A. Finucane Director May 14, 2026 A 591 0 0 $0
John E Gallina Director May 14, 2026 A 582 0 0 $0
Guy P Sansone Director May 14, 2026 A 15,106 0 0 $0
Scott J Kirby Director May 14, 2026 A 14,434 0 0 $0
DECOUDREAUX ALECIA A Director May 14, 2026 A 2,970 0 0 $0
David C Brown II Director May 14, 2026 A 129,316 0 0 $0
Roger N Farah Director Nov. 30, 2025 F 19,438 0 0 $0
Mary L Schapiro Director Nov. 21, 2024 A 7,585 0 0 $0
Jean Pierre Millon Director Nov. 21, 2024 A 4,514 0 0 $0
Nancy Ann Deparle Director Nov. 21, 2024 A 34,169 0 0 $0
Edward J Ludwig Director May 2, 2024 P 21,630 0 0 $0
William C Weldon Director Nov. 17, 2022 A 1,591 0 0 $0
Tony L White Director May 11, 2022 A 37,852 0 0 $0
David W Dorman Director May 11, 2022 A 109,875 0 0 $0
Larry J Merlo Director May 31, 2021 F 632,313 0 0 $0
Mark T Bertolini Director Nov. 20, 2019 A 13,773 0 0 $0
Richard M Bracken Director Nov. 20, 2019 A 15,348 0 0 $0
Richard J Swift Director Nov. 20, 2019 A 7,336 0 0 $0
Kristen Gibney Williams Director May 9, 2013 A 1,695 0 0 $0
C A Piccolo Director Dec. 14, 2012 S 181,461 0 0 $0
Marian L Heard Director Nov. 8, 2012 A 11,346 0 0 $0
Edwin M Banks Director March 15, 2012 M 23,187 0 0 $0
Terrence Murray Director Nov. 2, 2011 A 84,140 0 0 $0
Sheli Z Rosenberg Director Nov. 4, 2010 A 125,112 0 0 $0
JOYCE WILLIAM H Director Nov. 4, 2010 A 18,390 0 0 $0
Roger L Headrick Director May 23, 2007 P 2,200 0 0 $0
Alfred J Verrecchia Director March 7, 2007 A 0 0 0 $0
Don W Cornwell Director Dec. 22, 2006 A · 0 0 $0
Thomas P Gerrity Director Nov. 9, 2006 A 68,460 0 0 $0
Stanley P Goldstein Director May 11, 2006 J 590,967 0 0 $0
Terry R Lautenbach Director May 21, 2004 A 27,915 0 0 $0
Chris W Bodine · Feb. 18, 2009 A 23,132 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 165 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
IHF · iShares Trust 13.37% 1,839,467 SH Sept. 11, 2026 Daily
DUSA · Davis Fundamental ETF Trust 5.28% 642,932 NS July 31, 2026 N-PORT
GEND · Spinnaker ETF Series 4.47% 2,080 NS July 31, 2026 N-PORT
IYK · iShares Trust 4.25% 617,818 SH Sept. 11, 2026 Daily
CVGD · Elevation Series Trust 4.14% 54,893 NS July 31, 2026 N-PORT
FMTM · EA Series Trust 3.17% 76,503 NS July 31, 2026 N-PORT
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 2.83% 2,458 NS July 31, 2026 N-PORT
DWLD · Davis Fundamental ETF Trust 2.70% 158,312 NS July 31, 2026 N-PORT
SPDV · ETF Series Solutions 2.29% 28,879 NS July 31, 2026 N-PORT
RWL · Invesco Exchange-Traded Fund Trust … 2.03% 2,208,053 SH Oct. 23, 2026 Daily
VHT · VANGUARD WORLD FUND 1.94% 3,824,297 SH Aug. 19, 2026 Daily
FHLC · FIDELITY COVINGTON TRUST 1.92% 605,189 NS July 31, 2026 N-PORT
RPV · Invesco Exchange-Traded Fund Trust 1.87% 346,218 SH Oct. 23, 2026 Daily
REVS · Columbia ETF Trust I 1.68% 53,828 NS July 31, 2026 N-PORT
IXJ · iShares Trust 1.54% 670,400 SH Sept. 11, 2026 Daily
CURE · Direxion Shares ETF Trust 1.53% 25,107 NS July 31, 2026 N-PORT
RSPH · Invesco Exchange-Traded Fund Trust 1.52% 154,187 SH Oct. 23, 2026 Daily
PWV · Invesco Exchange-Traded Fund Trust 1.49% 293,457 SH Oct. 23, 2026 Daily
SPVM · Invesco Exchange-Traded Fund Trust 1.45% 21,286 SH Oct. 23, 2026 Daily
DVY · iShares Trust 1.37% 3,384,928 SH Sept. 11, 2026 Daily
VLUE · iShares Trust 1.35% 1,359,538 SH Sept. 11, 2026 Daily
CVAR · ETF Opportunities Trust 1.21% 4,966 NS July 31, 2026 N-PORT
GURU · Global X Funds 1.19% 6,951 NS July 31, 2026 N-PORT
BSCS · Invesco Exchange-Traded Self-Indexe… 1.13% 40,284,000 Oct. 23, 2026 Daily
RECS · Columbia ETF Trust I 1.09% 610,992 NS July 31, 2026 N-PORT
VRP · Invesco Exchange-Traded Fund Trust … 1.06% 31,197,000 Oct. 23, 2026 Daily
EQWL · Invesco Exchange-Traded Fund Trust 0.99% 296,395 SH Oct. 23, 2026 Daily
FEUS · FlexShares Trust 0.97% 10,395 NS July 31, 2026 N-PORT
VFVA · VANGUARD WELLINGTON FUND 0.95% 77,895 SH Aug. 19, 2026 Daily
SPXD · DBX ETF Trust 0.87% 660 NS Aug. 31, 2026 N-PORT
IUS · Invesco Exchange-Traded Self-Indexe… 0.86% 91,475 SH Oct. 23, 2026 Daily
FXG · First Trust Exchange-Traded AlphaDE… 0.82% 18,035 NS July 31, 2026 N-PORT
LSEQ · Harbor ETF Trust 0.80% 1,171 NS July 31, 2026 N-PORT
FTLS · First Trust Exchange-Traded Fund III 0.80% 190,028 NS July 31, 2026 N-PORT
SNPV · DBX ETF Trust 0.76% 22,283 NS Aug. 31, 2026 N-PORT
SPMO · Invesco Exchange-Traded Fund Trust … 0.76% 1,713,094 SH Oct. 23, 2026 Daily
VFMF · VANGUARD WELLINGTON FUND 0.75% 50,750 SH Aug. 19, 2026 Daily
MTUM · iShares Trust 0.75% 1,909,551 SH Sept. 11, 2026 Daily
UPSD · ETF Series Solutions 0.74% 8,286 NS July 31, 2026 N-PORT
FBCV · FIDELITY COVINGTON TRUST 0.72% 12,142 NS July 31, 2026 N-PORT
WLDR · Two Roads Shared Trust 0.71% 6,228 NS July 31, 2026 N-PORT
BSCU · Invesco Exchange-Traded Self-Indexe… 0.70% 20,817,000 Oct. 23, 2026 Daily
BSCR · Invesco Exchange-Traded Self-Indexe… 0.67% 31,166,000 Oct. 23, 2026 Daily
CATH · Global X Funds 0.63% 78,905 NS July 31, 2026 N-PORT
CLSE · Trust for Professional Managers 0.63% 60,376 NS Aug. 31, 2026 N-PORT
MGV · VANGUARD WORLD FUND 0.62% 801,966 SH Aug. 19, 2026 Daily
GSY · Invesco Actively Managed Exchange-T… 0.61% 24,935,000 Oct. 23, 2026 Daily
LSVD · ADVISORS' INNER CIRCLE FUND 0.58% 36,106 NS July 31, 2026 N-PORT
FFLV · FIDELITY COVINGTON TRUST 0.57% 900 NS July 31, 2026 N-PORT
PFIG · Invesco Exchange-Traded Fund Trust … 0.55% 715,000 Oct. 23, 2026 Daily
VYM · VANGUARD WHITEHALL FUNDS 0.55% 5,122,611 SH Aug. 19, 2026 Daily
JVAL · J.P. Morgan Exchange-Traded Fund Tr… 0.50% 40,184 NS July 31, 2026 N-PORT
PRF · Invesco Exchange-Traded Fund Trust 0.50% 531,023 SH Oct. 23, 2026 Daily
DEUS · DBX ETF Trust 0.50% 15,890 NS Aug. 31, 2026 N-PORT
VTV · VANGUARD INDEX FUNDS 0.49% 12,134,319 SH Aug. 19, 2026 Daily
DFUV · Dimensional ETF Trust 0.48% 710,848 NS July 31, 2026 N-PORT
DFLV · Dimensional ETF Trust 0.47% 302,533 NS July 31, 2026 N-PORT
IWX · iShares Trust 0.45% 185,452 SH Sept. 11, 2026 Daily
VOOV · VANGUARD ADMIRAL FUNDS 0.45% 293,814 SH Aug. 19, 2026 Daily
VUS · Virtus ETF Trust II 0.45% 768 NS July 31, 2026 N-PORT
BSCT · Invesco Exchange-Traded Self-Indexe… 0.45% 13,627,000 Oct. 23, 2026 Daily
QARP · DBX ETF Trust 0.42% 3,512 NS Aug. 31, 2026 N-PORT
IVE · iShares Trust 0.41% 2,119,397 SH Sept. 11, 2026 Daily
DIVB · iShares Trust 0.41% 87,120 SH Sept. 11, 2026 Daily
CHRI · Global X Funds 0.41% 310 NS July 31, 2026 N-PORT
JPUS · J.P. Morgan Exchange-Traded Fund Tr… 0.40% 17,702 NS July 31, 2026 N-PORT
IUSV · iShares Trust 0.39% 1,116,077 SH Sept. 11, 2026 Daily
VONV · VANGUARD SCOTTSDALE FUNDS 0.37% 774,792 SH Aug. 19, 2026 Daily
ESG · FlexShares Trust 0.37% 4,650 NS July 31, 2026 N-PORT
ILCV · iShares Trust 0.35% 49,213 SH Sept. 11, 2026 Daily
IWD · iShares Trust 0.33% 2,852,019 SH Sept. 11, 2026 Daily
GLBL · Pacer Funds Trust 0.32% 34 NS July 31, 2026 N-PORT
EGLE · Global X Funds 0.31% 65 NS July 31, 2026 N-PORT
VFMO · VANGUARD WELLINGTON FUND 0.30% 57,429 SH Aug. 19, 2026 Daily
SNPE · DBX ETF Trust 0.30% 92,710 NS Aug. 31, 2026 N-PORT
OEF · iShares Trust 0.26% 540,125 SH Sept. 11, 2026 Daily
INFO · Harbor ETF Trust 0.25% 20,350 NS July 31, 2026 N-PORT
MGC · VANGUARD WORLD FUND 0.25% 255,122 SH Aug. 19, 2026 Daily
ESGV · VANGUARD WORLD FUND 0.23% 290,253 SH Aug. 19, 2026 Daily
TOPC · iShares Trust 0.23% 777 SH Sept. 11, 2026 Daily
IWL · iShares Trust 0.22% 49,933 SH Sept. 11, 2026 Daily
QVML · Invesco Exchange-Traded Fund Trust … 0.22% 38,787 SH Oct. 23, 2026 Daily
VV · VANGUARD INDEX FUNDS 0.21% 1,490,162 SH Aug. 19, 2026 Daily
XYLD · Global X Funds 0.21% 64,877 NS July 31, 2026 N-PORT
XTR · Global X Funds 0.21% 96 NS July 31, 2026 N-PORT
XVV · iShares Trust 0.21% 14,653 SH Sept. 11, 2026 Daily
EUSA · iShares, Inc. 0.21% 41,666 SH Sept. 11, 2026 Daily
XRMI · Global X Funds 0.21% 990 NS July 31, 2026 N-PORT
PTLC · Pacer Funds Trust 0.21% 64,355 NS July 31, 2026 N-PORT
DFSU · Dimensional ETF Trust 0.21% 44,781 NS July 31, 2026 N-PORT
BBUS · J.P. Morgan Exchange-Traded Fund Tr… 0.20% 174,338 NS July 31, 2026 N-PORT
BKLC · BNY Mellon ETF Trust 0.20% 106,735 NS July 31, 2026 N-PORT
XYLG · Global X Funds 0.20% 1,250 NS July 31, 2026 N-PORT
VOTE · TCW ETF Trust 0.20% 21,382 NS July 31, 2026 N-PORT
ADME · ETF Series Solutions 0.20% 5,697 NS July 31, 2026 N-PORT
XCLR · Global X Funds 0.20% 69 NS July 31, 2026 N-PORT
VOO · VANGUARD INDEX FUNDS 0.20% 33,144,255 SH Aug. 19, 2026 Daily
TOV · EA Series Trust 0.20% 5,061 NS July 31, 2026 N-PORT
ACIO · ETF Series Solutions 0.20% 44,949 NS July 31, 2026 N-PORT
LRGF · iShares Trust 0.20% 76,567 SH Sept. 11, 2026 Daily
RSP · Invesco Exchange-Traded Fund Trust 0.20% 2,057,745 SH Oct. 23, 2026 Daily
DFUS · Dimensional ETF Trust 0.19% 389,482 NS July 31, 2026 N-PORT
VOXP · Advisors Series Trust 0.19% 108 NS July 31, 2026 N-PORT
SPUU · Direxion Shares ETF Trust 0.19% 4,814 NS July 31, 2026 N-PORT
VONE · VANGUARD SCOTTSDALE FUNDS 0.19% 212,337 SH Aug. 19, 2026 Daily
QDPL · Pacer Funds Trust 0.19% 30,732 NS July 31, 2026 N-PORT
EVUS · iShares Trust 0.19% 7,499 SH Sept. 11, 2026 Daily
IVV · iShares Trust 0.19% 16,082,099 SH Sept. 11, 2026 Daily
PBP · Invesco Exchange-Traded Fund Trust 0.19% 7,669 SH Oct. 23, 2026 Daily
PBUS · Invesco Exchange-Traded Fund Trust … 0.18% 204,155 SH Oct. 23, 2026 Daily
SIZE · iShares Trust 0.18% 8,166 SH Sept. 11, 2026 Daily
FEX · First Trust Exchange-Traded AlphaDE… 0.18% 27,242 NS July 31, 2026 N-PORT
ILCB · iShares Trust 0.18% 24,548 SH Sept. 11, 2026 Daily
VTI · VANGUARD INDEX FUNDS 0.18% 40,509,855 SH Aug. 19, 2026 Daily
VTHR · VANGUARD SCOTTSDALE FUNDS 0.18% 108,067 SH Aug. 19, 2026 Daily
EQAL · Invesco Exchange-Traded Fund Trust … 0.18% 15,049 SH Oct. 23, 2026 Daily
IWB · iShares Trust 0.17% 888,287 SH Sept. 11, 2026 Daily
IYY · iShares Trust 0.17% 54,746 SH Sept. 11, 2026 Daily
USCL · iShares Trust 0.17% 50,655 SH Sept. 11, 2026 Daily
FTA · First Trust Exchange-Traded AlphaDE… 0.17% 22,631 NS July 31, 2026 N-PORT
IWV · iShares Trust 0.17% 354,060 SH Sept. 11, 2026 Daily
TILT · FlexShares Trust 0.17% 34,918 NS July 31, 2026 N-PORT
DCOR · Dimensional ETF Trust 0.17% 53,112 NS July 31, 2026 N-PORT
DFAU · Dimensional ETF Trust 0.17% 197,043 NS July 31, 2026 N-PORT
ITOT · iShares Trust 0.17% 1,661,154 SH Sept. 11, 2026 Daily
HCMT · Direxion Shares ETF Trust 0.16% 8,880 NS July 31, 2026 N-PORT
APUE · Trust for Professional Managers 0.16% 43,074 NS Aug. 31, 2026 N-PORT
ACVF · ETF Opportunities Trust 0.16% 2,271 NS July 31, 2026 N-PORT
DYNF · BlackRock ETF Trust 0.16% 675,214 SH Sept. 11, 2026 Daily
PHDG · Invesco Actively Managed Exchange-T… 0.15% 1,007 SH Oct. 23, 2026 Daily
SPXL · Direxion Shares ETF Trust 0.15% 99,749 NS July 31, 2026 N-PORT
TOK · iShares Trust 0.14% 3,579 SH Sept. 11, 2026 Daily
OMFL · Invesco Exchange-Traded Self-Indexe… 0.14% 69,665 SH Oct. 23, 2026 Daily
KOKU · DBX ETF Trust 0.14% 11,834 NS Aug. 31, 2026 N-PORT
URTH · iShares, Inc. 0.13% 114,536 SH Sept. 11, 2026 Daily
DFAC · Dimensional ETF Trust 0.12% 539,188 NS July 31, 2026 N-PORT
ACWI · iShares Trust 0.12% 406,018 SH Sept. 11, 2026 Daily
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0.11% 1,069,623 SH Aug. 19, 2026 Daily
DXUV · Dimensional ETF Trust 0.10% 5,157 NS July 31, 2026 N-PORT
QLC · FlexShares Trust 0.09% 8,960 NS July 31, 2026 N-PORT
FAB · First Trust Exchange-Traded AlphaDE… 0.08% 1,368 NS July 31, 2026 N-PORT
CRBN · iShares Trust 0.05% 6,619 SH Sept. 11, 2026 Daily
FBCG · FIDELITY COVINGTON TRUST 0.05% 35,048 NS July 31, 2026 N-PORT
GLOF · iShares Trust 0.02% 478 SH Sept. 11, 2026 Daily
LGDX · Tidal Trust III 0.02% 251 NS July 31, 2026 N-PORT
GTOS · Invesco Actively Managed Exchange-T… 0.02% 21,000 Oct. 21, 2026 Daily
GTO · Invesco Actively Managed Exchange-T… 0.01% 419,000 Oct. 23, 2026 Daily
PEVC · Pacer Funds Trust 0.01% 3 NS July 31, 2026 N-PORT
NEAR · iShares U.S. ETF Trust 0.01% 600,000 SH Sept. 11, 2026 Daily
DFVX · Dimensional ETF Trust 0.01% 517 NS July 31, 2026 N-PORT
NPFE · Elevation Series Trust 0.00% 276 NS July 31, 2026 N-PORT
BIV · VANGUARD BOND INDEX FUNDS · · July 15, 2026 Daily
BLV · VANGUARD BOND INDEX FUNDS · · July 15, 2026 Daily
BSV · VANGUARD BOND INDEX FUNDS · · July 15, 2026 Daily
BND · VANGUARD BOND INDEX FUNDS · · July 15, 2026 Daily
VCRB · VANGUARD MALVERN FUNDS · · July 15, 2026 Daily
VPLS · VANGUARD MALVERN FUNDS · · July 15, 2026 Daily
VSDB · VANGUARD MALVERN FUNDS · · July 15, 2026 Daily
VGMS · VANGUARD MALVERN FUNDS · · July 15, 2026 Daily
VCSH · VANGUARD SCOTTSDALE FUNDS · · July 15, 2026 Daily
VCIT · VANGUARD SCOTTSDALE FUNDS · · July 15, 2026 Daily
VCLT · VANGUARD SCOTTSDALE FUNDS · · July 15, 2026 Daily
VTC · VANGUARD SCOTTSDALE FUNDS · · July 30, 2026 Daily
BNDW · VANGUARD SCOTTSDALE FUNDS · · July 30, 2026 Daily
VCEB · VANGUARD WORLD FUND · · July 30, 2026 Daily

CVS Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 32 analysts BUY
Median target $113.00 +22.5%
8 25.0% Strong Buy
20 62.5% Buy
4 12.5% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

25 analysts · 2026-10-27

Mean target $115.48 +25.1%

← Below all targets Current price $92.28
Low$103.00 Mean$115.48 High$145.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
CVS $100.87B 57.1 7.8% 0.44% 2.4% ·
CI $72.51B 12.4 11.2% 2.2% 14.4% ·
LH $20.62B 24.0 7.2% 6.3% 10.3% 28.8%
DGX $19.09B 19.8 11.8% 9.0% 14.2% ·
GH $13.34B -30.8 32.9% -42.4% 205.7% ·
LH $20.62B 24.0 7.2% 6.3% 10.3% 28.8%
BTSG $7.20B 43.0 28.2% 1.5% 10.8% 11.8%
DVA $7.79B 11.5 6.5% 5.5% -281.8% ·
HNGE $0 -6.0 50.6% -89.9% -299.8% 79.7%
CHE · 23.3 4.1% 10.5% 24.4% ·
HIMS · 63.7 59.0% 5.5% 23.3% 73.8%

Latest News Recent headlines mentioning this company

23

Trading Signals Recent buy/sell signals with entry price and risk/reward ratio

25

Live signal — the only filled card on screen.

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 5, 2026